Tickers

1. Composite Trajectory Verdict

Given AEVA's development-stage business model — characterized by minimal revenue, large operating losses, and dependence on external financing — all three financial statements carry roughly equal weight: the income statement shows whether the core technology is gaining commercial traction, the cash flow statement reveals the burn rate and financing dependency, and the balance sheet tracks the accumulating leverage and equity erosion that result.

Composite Trajectory: Mixed

Annual results show clear improvement: revenue nearly doubled to $18.1 million (10-K 2025, Consolidated Statements of Operations), gross loss narrowed to $0.7 million from $3.8 million, and operating loss improved 19% to $127.6 million (10-K 2025, Consolidated Statements of Operations). However, quarterly trends are divergent: six-month revenue grew 40% to $12.4 million and gross profit turned positive at $4.1 million (10-Q Q2 2026, Consolidated Statements of Operations), yet operating loss widened 7% to $69.7 million on a 49% surge in G&A (10-Q Q2 2026, Consolidated Statements of Operations). Cash generation remains deeply negative from operations, masked by large financing inflows ($128.6 million in FY2025; $114.5 million in H1 2026). The balance sheet reflects rising liabilities (convertible notes $96.7 million, warrant liabilities up to $74.0 million) and an accumulated deficit of $871.9 million, though a June 2026 public offering boosted equity to $27.5 million from $13.2 million (10-Q Q2 2026, Consolidated Balance Sheets). Improving revenue and gross margin are offset by expanding operating losses, volatile non-cash fair-value swings, and increasing leverage.

2. Red Flags

• Warrant liability fair-value volatility: Change in fair value of warrant liabilities drove a $21.5 million non-cash loss in FY2025 (10-K 2025, Consolidated Statements of Operations) and a $44.3 million loss in H1 2026 (10-Q Q2 2026, Consolidated Statements of Operations), making net loss an unreliable indicator of operating performance.
• Accumulated deficit growth: Deficit increased from $611.9 million (FY2024) to $757.3 million (FY2025) to $871.9 million (June 30, 2026) (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets), with no pathway to profitability disclosed.
• Reliance on dilutive/convertible financing: FY2025 financing cash flow of $128.6 million came from a $100 million convertible note and a $32.5 million private placement (10-K 2025, Consolidated Statements of Cash Flows); H1 2026 financing of $114.5 million came from a $108.8 million public offering (10-Q Q2 2026, Consolidated Statements of Cash Flows).
• Warrant liability explosion: Warrant liabilities rose from $8.3 million (Dec 2024) to $29.7 million (Dec 2025) to $74.0 million (June 2026) (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets), driven by stock-price appreciation on Series A warrants exercisable at $5.00.
• G&A expense acceleration: Six-month G&A jumped 49% to $22.6 million (10-Q Q2 2026, Consolidated Statements of Operations), outpacing revenue growth.
• Convertible note interest commenced: $2.4 million interest expense in H1 2026 (10-Q Q2 2026, Consolidated Statements of Operations) with semi-annual payments due, partially payable in shares causing further dilution.
• Deferred revenue collapse: Contract liabilities (deferred revenue) fell from $4.0 million to $0.3 million (10-K 2025, Note 9; 10-Q Q2 2026, Consolidated Balance Sheets), indicating limited near-term revenue visibility.

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual revenue nearly doubled to $18.1 million in FY2025 from $9.1 million in FY2024 (10-K 2025, Consolidated Statements of Operations), and gross loss narrowed to $0.7 million from $3.8 million. Total operating expenses fell 18% to $126.9 million, driven by a 17% R&D reduction and the absence of an $11.5 million litigation settlement (10-K 2025, Consolidated Statements of Operations). Operating loss improved 19% to $127.6 million. However, net loss benefited from a $1.7 million fair-value gain on share-subscription settlement and was distorted by a $21.5 million warrant fair-value loss (10-K 2025, Consolidated Statements of Operations). Quarterly trends show six-month revenue up 40% to $12.4 million with gross profit of $4.1 million (vs. a $2.4 million gross loss) (10-Q Q2 2026, Consolidated Statements of Operations), but operating loss widened to $69.7 million from $65.3 million as G&A surged 49% and R&D rose 7% (10-Q Q2 2026, Consolidated Statements of Operations). Net loss improved to $114.6 million from $227.6 million primarily because the prior year included a $70.0 million fair-value loss on the LGIT share subscription liability (10-Q Q2 2026, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash burn increased annually to $115.1 million in FY2025 from $106.9 million in FY2024 (10-K 2025, Consolidated Statements of Cash Flows), but improved modestly to $57.0 million in H1 2026 from $60.6 million in H1 2025 (10-Q Q2 2026, Consolidated Statements of Cash Flows). Investing cash flow swung from a $97.9 million inflow in FY2024 (largely maturities of marketable securities) to a $29.9 million inflow in FY2025, then to an $86.5 million outflow in H1 2026 as the company purchased $148.1 million of securities (10-K 2025, Consolidated Statements of Cash Flows; 10-Q Q2 2026, Consolidated Statements of Cash Flows). Financing inflows surged: $128.6 million in FY2025 (convertible notes $100 million, LGIT placement $32.5 million) and $114.5 million in H1 2026 (public offering $109.2 million net) (10-K 2025, Consolidated Statements of Cash Flows; 10-Q Q2 2026, Consolidated Statements of Cash Flows). Net cash change was +$43.4 million in FY2025 but -$29.1 million in H1 2026, leaving cash and marketable securities at $177.9 million at June 30, 2026 (10-Q Q2 2026, Consolidated Balance Sheets). The company remains entirely dependent on external capital to fund operations.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew from $147.5 million (Dec 2024) to $179.7 million (Dec 2025) to $227.8 million (June 2026) (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Cash and marketable securities rose from $112.0 million to $121.9 million to $177.9 million over the same periods (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). However, total liabilities expanded sharply from $48.1 million to $166.5 million to $200.3 million, driven by the $100 million convertible notes (carrying value $96.7–$96.9 million) and warrant liabilities increasing from $8.3 million to $29.7 million to $74.0 million (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Stockholders' equity fell from $99.4 million to $13.2 million, then recovered to $27.5 million after the June 2026 offering (10-K 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). The accumulated deficit reached $871.9 million. The Facility Agreement with Sylebra provides up to $125 million of preferred stock capacity through November 2026, but no draws have been reported (10-K 2025, MD&A; 10-Q Q2 2026, MD&A).

6. Data Gaps

• Quarterly income statement and cash flow data for Q1 2026, Q3 2025, and Q4 2025 (standalone quarters) to assess intra-year seasonality and trend consistency.
• Detailed breakdown of the $7.5 million joint development agreement receivable and the $3.8 million loss recognized on it (referenced in 10-K 2025 Note 1 and 10-Q Q2 2026 MD&A but not fully quantified by period).
• Terms and potential dilution from the Sylebra Facility Agreement preferred stock (dividend rate, conversion price, liquidation preference) beyond the summary in Note 10.
• Revenue concentration by customer for the most recent quarters (only annual concentration disclosed in 10-K 2025 Note 2).
• Schedule of convertible note interest payments in shares vs. cash and the resulting share-count impact.
• Fair-value methodology details for warrant liabilities (Level 3 inputs) to assess sensitivity to stock-price volatility.